<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275547</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB28/10</org_study_id>
    <nct_id>NCT01275547</nct_id>
  </id_info>
  <brief_title>The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam</brief_title>
  <acronym>NASKEMI</acronym>
  <official_title>The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction&#xD;
&#xD;
      Ketamine is an old and generally well accepted analgesic used in the intra- and perioperative&#xD;
      setting. Several studies demonstrated the effectiveness of ketamine in the postoperative&#xD;
      setting.&#xD;
&#xD;
      A new formulation of S-ketamine as an intranasal spray device was tested in our hospital in 8&#xD;
      healthy volunteers (unpublished data, EKBB 351/08). 20 mg of S-ketamine were administered&#xD;
      intranasally and compared with S-ketamine i.v. and i.m.. None of the volunteers had serious&#xD;
      adverse effects or complications. A preliminary data analysis shows a clear analgesic effect&#xD;
      and good absorption of the intranasal S-ketamine.&#xD;
&#xD;
      As a next step we would like to investigate the effect of S-ketamine intranasal spray&#xD;
      combined with midazolam intranasal spray in a group of postoperative spinal surgery patients.&#xD;
      The rational for the combination of intranasal S-ketamine and midazolam is the well known&#xD;
      midazolam antagonising effect of ketamine induced psychomimetic adverse effects. Furthermore&#xD;
      we know from other studies (EKBB 106/06) that midazolam intranasal spray has relaxant and&#xD;
      anxiolytic effects. As far as we know, this is the first study which will examine the&#xD;
      combination of S-ketamine and midazolam intranasal sprays in adult patients.&#xD;
&#xD;
      Study work plan&#xD;
&#xD;
      This prospective, randomized, double-blinded non inferiority study will address pain ratings&#xD;
      and patient satisfaction in a postoperative setting in two treatment scenarios:&#xD;
&#xD;
        1. Alternating S-ketamine intranasal unit-dose spray (6 mg per dose) with midazolam&#xD;
           intranasal spray (0.75 mg per dose) patient controlled application with a lock-out&#xD;
           interval of 20 minutes between two applications and placebo patient controlled analgesia&#xD;
           (PCA) with a lock-out interval of 12 minutes with saline 0.9% i.v. for 72 hours or until&#xD;
           40 unit-dose sprays are delivered&#xD;
&#xD;
        2. PCA with 2 mg morphine with a lock-out interval of 12 minutes i.v. with placebo&#xD;
           intranasal spray (saline 0.9% + chitosan) with a minimum lock-out interval of 20 minutes&#xD;
           for 72 hours or until 40 unit-dose sprays are delivered&#xD;
&#xD;
      Patient number&#xD;
&#xD;
      We will examine 36 patients, 18 patients in each group. The study duration for an individual&#xD;
      patient will be at latest 72 hours, the total study duration is 4 to 5 months.&#xD;
&#xD;
      Study importance&#xD;
&#xD;
      An intranasal spray is an ideal application form for surgery patients, either in- or&#xD;
      outpatients. On the other hand, ketamine and S-ketamine is quite often used in the&#xD;
      perioperative setting as a rescue analgesic. In higher doses it could be used as an emergency&#xD;
      tool in emergency prehospital medicine. In the perioperative setting it is important to&#xD;
      evaluate the efficacy and safety of S-ketamine intranasal spray combined with midazolam&#xD;
      intranasal spray in patients.&#xD;
&#xD;
      If our study shows that S-ketamine intranasal spray is effective as an analgesic and has good&#xD;
      patient acceptance, S-ketamine intranasal spay could be considered as an alternative,&#xD;
      completely non-invasive analgesic procedure in a postoperative outpatient setting. As a&#xD;
      consequence development of a nasal multidose-applicator combining S-ketamine and midazolam&#xD;
      would be of interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale 24 hours after surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>NRS after 24 hours after finishing surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of PCA boli</measure>
    <time_frame>72 hours</time_frame>
    <description>Amount of demanded / delivered unit doses of intranasal S-ketamine&#xD;
/ midazolam or morphine PCA-boli</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Analgesia, Patient-controlled</condition>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>S-ketamine &amp; midazolam spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine, patient controlled analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>morphine as an active comparator as a patient controlled analgesia system</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>s-ketamine &amp; midazolam</intervention_name>
    <description>s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal</description>
    <arm_group_label>S-ketamine &amp; midazolam spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine PCA</intervention_name>
    <description>2 mg Morphine i.v. all 12 minutes as a patient controlled system</description>
    <arm_group_label>morphine, patient controlled analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spinal surgery patients with:&#xD;
&#xD;
               -  decompression because of spinal stenosis&#xD;
&#xD;
               -  laminectomy because of spinal stenosis&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  BMI 18 - 39.9 (kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to give written informed consent&#xD;
&#xD;
               -  Known drug allergies or intolerance to the study medications morphine, midazolam,&#xD;
                  ketamine, paracetamol or metamizol&#xD;
&#xD;
               -  Known allergy to crustacea or chitosan&#xD;
&#xD;
               -  Patients using snuff at a regularly basis&#xD;
&#xD;
               -  Recreational drug addiction or abuse&#xD;
&#xD;
               -  Preexisting opioid (tramadol excluded), ketamine or midazolam therapy&#xD;
&#xD;
               -  General physical condition â‰¥ ASA IV&#xD;
&#xD;
               -  Serious intranasal or epipharyngeal problems&#xD;
&#xD;
               -  Mental / psychiatric disorder&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Patients with renal failure (clearance &lt; 30 ml/min)&#xD;
&#xD;
               -  Patients with liver failure (MELD score &gt; 25) Investigational Product Morphine /&#xD;
                  S-ketamine / midazolam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Ruppen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Basel, Switzerland</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient controlled analgesia</keyword>
  <keyword>Morphine</keyword>
  <keyword>S-Ketamine intranasal</keyword>
  <keyword>Midazolam intranasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

